Dyadic International (NASDAQ:DYAI) Major Shareholder Francisco Trust Under Agreemen Sells 26,340 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 26,340 shares of Dyadic International stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $2.43, for a total transaction of $64,006.20. Following the completion of the transaction, the insider owned 3,522,188 shares of the company’s stock, valued at $8,558,916.84. This represents a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Trading Up 10.1%

Shares of DYAI stock opened at $1.06 on Tuesday. The stock has a market capitalization of $38.81 million, a price-to-earnings ratio of -4.70 and a beta of 1.15. The company’s fifty day simple moving average is $0.77 and its two-hundred day simple moving average is $0.83. Dyadic International Inc. has a 1 year low of $0.65 and a 1 year high of $1.35. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. As a group, analysts anticipate that Dyadic International Inc. will post 0.13 earnings per share for the current year.

More Dyadic International News

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations continue to validate its C1 protein-expression platform and expand its commercial opportunity, reinforcing the investment case around its core biotechnology technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: The company’s latest reported quarterly results were mixed, with revenue beating expectations but earnings per share missing estimates, leaving investors focused on future commercialization progress rather than near-term profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreemen disclosed additional stock sales, adding to recent insider selling that may create some caution around the stock’s near-term momentum.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Dyadic International currently has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Trading of Dyadic International

Several institutional investors and hedge funds have recently modified their holdings of DYAI. Bank of America Corp DE grew its holdings in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Marathon Capital Management bought a new stake in Dyadic International during the third quarter valued at approximately $41,000. Geode Capital Management LLC lifted its position in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in Dyadic International in the 3rd quarter worth approximately $190,000. Finally, Apis Capital Advisors LLC bought a new position in shares of Dyadic International in the 3rd quarter worth $1,817,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.